Very promising Results for Resistant Lung Cancer

18/04/2016 - 3 minutes

Ariad has presented updated results of an ongoing phase I/II trial for lung cancer, scoring 100% in one-year overall survival.

ariad_lung_cancer_alk_brigotinibAriad Pharmaceuticals is developing small molecules to treat difficult cancers, using computational and structural biology research. It is based in Cambridge (US) and Lausanne (Switzerland).

One of the hard-to-treat cancers that Ariad is targeting is a type of non-small cell lung cancer (NSCLC), which is characterized by abnormal expression of the proto-oncogene ALK. 

This gene codes a protein (anaplastic lymphoma kinase) which is not normally expressed in healthy adult tissues – making it a promising target in Cancer.

Brigatinib is a small-molecule drug taking advantage of this target, and the strategy was recognized as a Breakthrough Therapy by the FDA. Though applicable to a range of cancers with ALK activity (ALK+), the most advanced clinical trials are in NSCLC.

Now, Ariad is presenting its updated results for brigatinib’s phase I/II trial which ran across the US and in 1 centre in Spain.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member